Glucagon-like peptide-1 (GLP-1) analogs have emerged as a compelling therapeutic target for managing metabolic disorders. These naturally occurring substances are secreted by the gut in response to food intake, stimulating insulin secretion and suppressing glucagon output. GLP-1 peptides possess promising therapeutic results in treating type 2 diab